Technical Analysis for RVNC - Revance Therapeutics, Inc.

Grade Last Price % Change Price Change
F 13.79 -0.14% -0.02
RVNC closed down 39.19 percent on Monday, October 18, 2021, on 19.75 times normal volume. The bears made the stock sink to a new 52-week low.
Earnings due: Nov 8
*** please verify all earnings dates ***

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down
Historical RVNC trend table...

Date Alert Name Type % Chg
New 52 Week Closing Low Bearish -0.14%
Volume Surge Other -0.14%
Calm After Storm Range Contraction -0.14%
Lower Bollinger Band Walk Weakness -0.14%
New 52 Week Low Weakness -0.14%
Wide Bands Range Expansion -0.14%
Below Lower BB Weakness -0.14%
Gapped Down Weakness -0.14%
New Downtrend Bearish -39.28%
Calm After Storm Range Contraction -39.28%
Older End-of-Day Signals for RVNC ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Possible Inside Day 36 minutes ago
2x Volume Pace about 5 hours ago
1.5x Volume Pace about 5 hours ago
3x Volume Pace about 5 hours ago
10x Volume Pace about 5 hours ago
View Earlier Intraday Alerts

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Revance Therapeutics, Inc. Description

Revance Therapeutics, Inc., a biopharmaceutical company, focuses on the development, manufacture, and commercialization of novel botulinum toxin products for various aesthetic and therapeutic applications worldwide. Its lead product candidate is RT001, a topical gel formulation of botulinum toxin type A, which is in Phase III clinical trials for the treatment of crow's feet lines; has completed initial Phase II clinical trials for the treatment of hyperhidrosis and for the prevention of migraine headache; and has completed Phase I clinical trials for the treatment of other indications, such as neuropathic pain and rhinitis. The company is also developing RT002, a novel injectable formulation of botulinum toxin type A, which is being tested in the four-cohort Phase I/II clinical dose escalation trials for the treatment of glabellar lines. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was founded in 1999 and is based in Newark, California.


Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Drugs Pain Neuropathic Pain Toxins Migraine Plastic Surgery Headache Therapeutic Applications Botulinum Toxin Botulism Migraine Headache Hyperhidrosis Neurotoxins Rhinitis

Is RVNC a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 33.81
52 Week Low 13.01
Average Volume 869,077
200-Day Moving Average 28.10
50-Day Moving Average 26.52
20-Day Moving Average 25.92
10-Day Moving Average 23.42
Average True Range 2.26
ADX 29.34
+DI 8.43
-DI 55.78
Chandelier Exit (Long, 3 ATRs) 23.23
Chandelier Exit (Short, 3 ATRs) 19.78
Upper Bollinger Bands 33.40
Lower Bollinger Band 18.44
Percent B (%b) -0.31
BandWidth 57.70
MACD Line -2.02
MACD Signal Line -0.95
MACD Histogram -1.0762
Fundamentals Value
Market Cap 919.04 Million
Num Shares 66.5 Million
EPS -3.71
Price-to-Earnings (P/E) Ratio -3.72
Price-to-Sales 300.67
Price-to-Book 4.29
PEG Ratio -0.64
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 16.39
Resistance 3 (R3) 16.41 15.57 15.96
Resistance 2 (R2) 15.57 14.91 15.56 15.82
Resistance 1 (R1) 14.69 14.51 14.27 14.67 15.67
Pivot Point 13.85 13.85 13.64 13.84 13.85
Support 1 (S1) 12.97 13.19 12.55 12.95 11.95
Support 2 (S2) 12.13 12.79 12.12 11.80
Support 3 (S3) 11.25 12.13 11.66
Support 4 (S4) 11.23